AZN vs ZYME: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: AZN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AZN and ZYME share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AZN and ZYME exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.

Full AZN guide

Zymeworks is a biotechnology company incorporated in Delaware with roughly 231 employees, built around protein engineering: bispecific antibodies and antibody-drug conjugates aimed mainly at cancer. Its one approved medicine, zanidatamab, is sold as Ziihera by Jazz Pharmaceuticals in the United States and other licensed markets and by BeOne Medicines across its Asia-Pacific territories. Zymeworks does not market anything itself. Revenue arrives as tiered royalties (10% to 20% of Jazz's net sales, up to 19.5% of BeOne's) and as regulatory and commercial milestone payments, while the wholly owned pipeline of ADCs stays in early clinical testing.

Full ZYME guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.
• ZYME drivers: Ziihera moves into first-line gastric cancer; A second cash-generating asset via Theravance.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. For ZYME, zymeworks is not profitable and is not close to it on current product economics: the second quarter of 2026 produced a net loss of about $45.0 million on roughly $4.6 million of revenue, and operations run on a ~$322.5 million cash and securities balance plus lumpy partner payments rather than on product profits.

Pick AZN if you believe its drivers more; ZYME if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AZN and ZYME guides.

AZN. Figures are approximate and tied to the asOf date; confirm live numbers before acting. AstraZeneca trades as a growth-oriented large-cap pharma, so its valuation reflects confidence in the pipeline delivering on the $80 billion 2030 goal more than any single current metric. A patent cliff early next decade means today's revenue base is not guaranteed to persist, so how you weigh future launches matters more than trailing multiples.

ZYME. The sales multiple is close to meaningless here because the revenue line mixes a small growing royalty with large one-off milestones, so it swings by an order of magnitude between years. A more useful frame is the two pieces separately: royalties of ~$1.8 million in the second quarter that track Jazz's Ziihera sales, and a milestone stack of up to ~$1.3 billion that pays only on events. Second-quarter research and development spending fell about 20% year over year to ~$27.4 million while general and administrative costs rose to ~$19.3 million, and management stopped issuing cash runway guidance in August 2026, citing the shift toward a revenue-generating model.

Headline figures (approximate, Jul 2026): AZN shows revenue (ttm) Around $60 billion; 2025 total revenue was about $58.7 billion, up roughly 9%, with Q1 2026 up about 8% at constant currency, growth drivers Oncology (Tagrisso, Imfinzi, Calquence, Enhertu, Lynparza), rare disease (Ultomiris, Soliris) and metabolic launches; company ambition of $80 billion revenue by 2030, margins/profitability Solidly profitable large-cap pharma; heavy, sustained R&D spending funds the pipeline that the 2030 target depends on, dividend Pays a regular dividend; recent yield roughly 2%, modest for the sector but backed by large, growing cash flows; ZYME shows revenue (ttm) ~$37.1M, royalty revenue (q2 2026) ~$1.8M, net loss (q2 2026) ~$45.0M, cash and marketable securities (jun 30, 2026) ~$322.5M.

AZN and ZYME are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AZN and ZYME exposure against your real portfolio. It is not an investment adviser.